Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

OBJECTIVES: Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those i...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieslawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Lee, Younju, Rho, Young Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867419/
https://www.ncbi.nlm.nih.gov/pubmed/29042358
http://dx.doi.org/10.1136/annrheumdis-2017-211741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867419/
https://www.ncbi.nlm.nih.gov/pubmed/29042358
http://dx.doi.org/10.1136/annrheumdis-2017-211741

Ejemplares similares